Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

Paradigm shift: a changing CDK4/6 inhibitor treatment landscape – NOW ONLINE!

12.07.2023

Cyclin-dependent kinase (CDK) 4/6 inhibitors have proven to be game changer as targeted cancer therapy of patients with hormone receptor-positive breast cancer and they have established as standard of care for the treatment of advanced HR+ breast cancer. Also, mechanisms of resistance to CDK4/6 inhibitors, biomarker analyses to better select patients who derive the greatest benefit from CDK4/6 inhibitors, in both early and advanced settings, and more issues have been elucidated.